Not surprisingly then, the dual administration of karonudib and anti-PD-L1 was more potent in halting mesothelioma progression by triggering more profound CD8+ T cell and DC activation, encouraging M1 polarization and reducing Treg suppressive actions compared to single therapies. Here, CD8A is linked to mesothelioma.